Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzyme Engineering . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN117737014B reveals enzyme mutant for Compound I synthesis. Offers high purity and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN117165543A reveals a high-yield biocatalytic route for furfuryl alcohol. Discover cost-effective manufacturing and supply chain advantages for fine chemical intermediates.
Patent CN116640737A reveals novel BsER mutants for asymmetric reduction. Enables cost reduction in API manufacturing with high stereoselectivity and supply reliability.
Patent CN116640737A reveals novel BsER mutants for chiral ketone reduction. Enables high-purity pharmaceutical intermediates with reduced manufacturing costs and enhanced supply reliability.
Patent CN108118035B reveals high-concentration enzymatic route reducing costs and improving purity for global supply chains.
Novel enzyme catalytic system synthesizes organic selenides greenly. Offers supply chain reliability and cost reduction in pharmaceutical intermediate manufacturing without heavy metals.
Patent CN116103255A details engineered KdAKR mutants for high-yield synthesis of tert-butyl 6-chloro-(3R,5S)-dihydroxyhexanoate, offering superior stereoselectivity and thermal stability for statin production.
Patent CN109402212B reveals a novel fusion enzyme method for TUDCA production, offering significant cost reduction in bile acid manufacturing and reliable supply chain scalability.
Patent CN115109760A discloses engineered monoamine oxidase for Boceprevir and Nirmatrelvir intermediates, offering superior catalytic efficiency and cost-effective manufacturing solutions.
Patent CN115786313B reveals enhanced nitrilase mutant for 2-chloronicotinic acid. Delivers significant yield improvements and green manufacturing advantages for supply chains.
Patent CN110229796B details enzymatic synthesis for high-purity duloxetine intermediates. Offers cost reduction and supply chain reliability for pharma manufacturing.
Patent CN109943542A reveals enhanced ADH for Atazanavir. Lower cost, green synthesis, high purity pharmaceutical intermediates for global supply chains.
Patent CN111154746B reveals high-activity amidase mutants enabling green, scalable production of 2-chloronicotinic acid for agrochemical and pharmaceutical applications.
Patent CN109576234B reveals a highly active V77A mutant enzyme enabling efficient biosynthesis of hydroxylated amino acids, offering significant cost reduction in API manufacturing and reliable supply chain solutions.
Patent CN118222532A reveals efficient biosynthesis. Reduces costs and improves supply chain for high-purity Rebaudioside M8 manufacturing.
Patent CN108486075A details a mutant enzyme for statin side chains, offering enhanced catalytic efficiency and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN108866028B details a mutant amino lyase for producing (R)-3-aminobutyric acid. This biocatalytic route offers superior stereoselectivity and cost efficiency for Dolutegravir intermediates.
Patent CN115851685A reveals a breakthrough nitrilase mutant for efficient 3-hydroxy-3-methylbutyric acid production, offering significant cost reduction and green manufacturing advantages.
Patent CN112175892B reveals a novel co-expression engineering bacterium reducing PLP dependency. Discover cost-effective antibiotic intermediate manufacturing solutions.
Patent CN114736882B reveals high-efficiency biocatalysis for antiviral intermediates. Offers supply chain stability and cost reduction in API manufacturing without heavy metals.